[CAS NO. 96389-69-4] Crisnatol mesylate
PRODUCTS SPECIFICATIONS [96389-69-4]
DESCRIPTION [96389-69-4]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 441.54 |
| Molecular Formula | C24H27NO5S |
| SMILES | OCC(C)(NCC1=C2C=CC=CC2=C3C(C4=CC=CC=C4C=C3)=C1)CO.OS(=O)(C)=O |
Summary
In Vitro
Crisnatol (1.3 μg/mL; 24-72 h) mesylate inhibits the replication of HepG2 cells, decreases cell viability by 35% [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [2]
| Cell Line: | HepG2 cells |
| Concentration: | 1.3 μg/mL |
| Incubation Time: | 24 hours, 48 hours, 72 hours, and 126 hours |
| Result: | Inhibited cell viability at 48 hr. |
In Vivo
Crisnatol (25 mg/kg; p.o.; single dose) mesylate shows oral activity and shows stable metabolite profile extract of rat feces by autoradiography [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References
- [1] Adams DJ. In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a new DNA intercalator. Cancer Res. 1989 Dec 1;49(23):6615-20.
- [2] Patel DK, et al. Metabolism of a novel antitumor agent, crisnatol, by a human hepatoma cell line, Hep G2, and hepatic microsomes. Characterization of metabolites. Biochem Pharmacol. 1991 Jul 5;42(2):337-46.
- [3] Patel DK, et al. Disposition, metabolism, and excretion of the anticancer agent crisnatol in the rat. Drug Metab Dispos. 1991 Mar-Apr;19(2):491-7.